Judicious Use of Ozanimod for Ulcerative Colitis and Multiple Sclerosis
ACG CASE REPORTS JOURNAL(2024)
摘要
Clinical trials have demonstrated the efficacy of ozanimod, an oral sphingosine-1-phosphate receptor modulator, for the treatment of moderate-to-severe ulcerative colitis. Infrequently does an opportunity present itself to use one drug for two simultaneous disease states, proving especially beneficial in the case of this patient intolerant of numerous established therapies for ulcerative colitis. This case report describes the successful use of ozanimod for both ulcerative colitis and multiple sclerosis, achieving clinical remission in both diseases.
更多查看译文
关键词
Ozanimod,ulcerative colitis,inflammatory bowel disease,multiple sclerosis,sphingosine-1-phosphate receptor modulator
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要